Klaria Pharma

SAF is already protected by granted patents in the major market territories, such as the EU and US and the granting of the second patent broadens these protections.  Patent protection of a marketed product is seldom through a single patent.  Broadening protections through additional patents allows Klaria more flexibility in manufacturing, but more importantly it allows Klaria to identify and prosecute patent infringement and discourages development of similar, competing products without Klaria's consent.

Earlier this year, Klaria announced a positive opinion on both novelty and inventive step, the fundamental requirements of a valid patent, on the third patent in the SAF patent family.  The aim of the third patent is to protect the specific properties of the marketed product and to extend the patent protection and thus market exclusivity to 2045.  Klaria looks forward to announcing progress on this patent in the future.